REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety profile HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) can ...

公司战略与重组 - Kenadyr Metals将更名为Algo Grande Copper Corp，并申请在TSXV重新上市 [2][5][16] - 公司专注于北美高品位铜矿战略，通过数据驱动勘探释放股东价值 [3][22] - 公司已签署最终协议收购Adelita项目剩余20%权益，实现100%控股 [2][9][12] Adelita项目详情 - Adelita项目位于Sonora-Arizona铜矿带，面积5,985公顷，拥有近地表高品位Cu-Au-Ag矽卡岩系统 [2][10] - 项目包含Cerro Grande矽卡岩发现区，历史钻探结果显示高品位矿化：47.64米@1.05% Cu, 0.46 g/t Au, 46.00 g/t Ag [10] - 项目区域内存在6公里未测试矽卡岩靶区和4.5公里斑岩相关地球物理异常 [10][23] 融资与股权结构 - 公司启动300万美元融资，发行认购凭证，价格为0.375加元/份 [13][14] - 收购20%权益的对价包括313,953普通股(价值135,000加元)和1%的净冶炼回报权利金 [11] - 融资资金将用于支付项目义务、勘探支出和一般营运资金 [14] 管理团队与技术力量 - 技术团队由MAG Silver联合创始人Peter Megaw博士领导 [5][6] - 董事会新增Gord Neal，他在金属和矿业领域拥有30年经验，曾为资源公司融资超过7.5亿美元 [3][5] - 管理团队包括Tim McCutcheon(CEO)和Kevin Ma(执行董事)，合计拥有50年矿业和资本市场经验 [6] 项目优势与基础设施 - 项目位于墨西哥Sonora州，该州占全国铜产量的80% [10] - 项目周边有道路、电网、水源，距离深水港Guaymas约300公里 [10] - 靠近区域冶炼基础设施，可提供高品位补充材料 [10] 历史数据与勘探计划 - 项目已投入800万美元历史勘探数据，包括7,000米钻探和广泛地球物理调查 [7][23] - 勘探许可和社会许可证已获批准，首期钻探计划定于2025年秋季 [10] - 历史数据正通过AI辅助3D地球物理建模进行重新处理 [23]

Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak’s initial non-binding proposal.Board unanimously recommends shareholders vote “FOR” the Arrangement.Shareholders are encouraged to review the circular carefully ...

MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced a long-term strategic partnership with Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in advanced cardiovascular imaging solutions. The collaboration reflects Circle CVI’s commitment to leveraging trusted, high-quality data to drive innovation in cardiac diagnostics, treatment planning, and AI model development with data b ...

Series RIKV 25 1119RIKV 26 0318Settlement Date 08/20/202508/20/2025Total Amount Allocated (MM) 16,08819,800All Bids Awarded At (Price / Simple interest) 98.096/7.67995.728/7.650Total Number of Bids Received 1820Total Amount of All Bids Received (MM) 18,18825,800Total Number of Successful Bids <td colspan="3" style="border-right: solid black 1pt ; border-left: solid black 1 ...

TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to announce promising results from a program of metallurgical testing undertaken in collaboration with Dundee Sustainable Technologies (“DST”), a subsidiary of Dundee Corporation (TSX: DC.A), to evaluate the effectiveness of DST’s Glasslock Process™ on a high-grade sample from the Joss deposit at the Company’s Beartrack-Arnett Gold Project (“Beartrack-Arnett” or, the “Project”) ...

-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Score on Day 7, a 5.8-Point Greater Reduction Than Patients Treated with 1.5mg Dose (p=0.0094) -- -- Clinically Meaningful Reductions in MADRS Observed for RE104 30mg on the First Day Following Administration and Maintained Through Day 28 Follow-Up -- -- RE104 Observed to be Generally Well-Tolerated with No Serious Adverse Events; 92.7% of Patients Ready ...

TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to announce promising results from a program of metallurgical testing undertaken in collaboration with Dundee Sustainable Technologies (“DST”), a subsidiary of Dundee Corporation (TSX: DC.A), to evaluate the effectiveness of DST’s Glasslock Process™ on a high-grade sample from the Joss deposit at the Company’s Beartrack-Arnett Gold Project (“Beartrack-Arnett” or, the “Project”) ...

TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) announced the appointment of Jane Skoblo as a director of the Company effective August 13, 2025. Ms. Skoblo will serve on both the Audit and Compensation & Organizational Development Committees of Mattr. Ms. Skoblo’s addition to the Board allows for an orderly transition as Laura Cillis, current Director and Audit Committee Chair, intends to retire from the Board at the Company’s next Annual General Meeting. Ms. Sk ...

交易概述 - Theratechnologies宣布已与CB Biotechnology LLC签订收购协议 收购方为Future Pak LLC关联公司 交易将通过法定计划安排进行 [1][2] - 收购对价包括每股3.01美元现金 加上每股最高1.19美元的或有价值权(CVR) 总对价最高可达每股4.20美元 [3] - 特别股东大会定于2025年9月12日以混合形式召开 股东需在2025年9月10日前提交投票委托书 [1][16] 交易条款细节 - 现金部分提供即时流动性 CVR部分与EGRIFTA和Trogarzo特许经营权价值挂钩 最高支付总额为6500万美元 [3][11] - 总对价较2025年4月10日纳斯达克收盘价溢价216% 较截至该日的30日成交量加权平均股价溢价165% [7][11] - 交易需获得66⅔%以上出席股东投票通过 且需多数非关联股东批准 [14] 公司治理与股东支持 - 特别委员会在Barclays和Raymond James提供公平意见后一致推荐该交易 认为其符合公司最佳利益且对股东公平 [5][6] - 公司高管董事合计持有524,266股(占1.14%)已签署支持协议 Soleus Capital Master Fund持有10.4%股份也表示支持 [9][10] - 交易经过2024年2月至7月的定向市场检查 2024年下半年与5家潜在收购方接触 最终通过非独家销售流程收到两份最终报价 [11] 交易背景与 rationale - 纳斯达克上市生物制药微市值公司面临融资挑战 低交易量和历史低估股价阻碍新机构投资者进入 [11] - 公司曾寻求商业合作伙伴和融资来源 多个第三方表示收购兴趣 经过多月流程最终选择Future Pak报价 [11] - 特别委员会和董事会认为该条款是能从Future Pak获得的最佳条件 经过广泛谈判和财务法律建议 [11] 文件与信息获取 - 管理层委托通告已提交并寄送 包含交易背景 委员会推荐原因等详细信息 [1][13] - 安排计划和协议可在SEDAR+ EDGAR及公司网站获取 股东可联系Laurel Hill Advisory Group获取投票协助 [15][17]